SpringerLink
Log in

Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Metastasis to the leptomeninges occurs in many common cancers, including leukemia; lung, breast, and gastrointestinal cancers; and tumors of the brain. By way of the flow of cerebrospinal fluid, leptomeningeal metastasis spreads throughout the neuraxis. Consequently, therapy for leptomeningeal metastasis must be directed to the entire central nervous system (CNS). Treatment often consists of involved-field radiotherapy, systemic chemotherapy, and intrathecal chemotherapy. However, because meningeal spread occurs most often in advanced disease, treatment is mainly palliative, except in childhood leukemia, where durable remission has been reported. This article outlines the role of systemic and intrathecal chemotherapy in patients with leptomeningeal metastases. Strategies for symptom management in these patients are also described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Evans A, Gilbert E, Zandstra R: The increasing incidence of central nervous system leukemia in children. Cancer 1970, 26:404–407.

    Article  PubMed  CAS  Google Scholar 

  2. Posner J, Chernik N: Intracranial metastases from systemic cancer. Adv Neurol 1978, 19:579–592.

    PubMed  CAS  Google Scholar 

  3. Boyle R, Thomas M, Adams J: Diffuse involvement of the leptomeninges by tumour: a clinical and pathological study of 63 cases. Postgrad Med J 1980, 56:149–158.

    PubMed  CAS  Google Scholar 

  4. Bigner S, Johnston W: The cytopathology of cerebrospinal fluid. Acta Cytol 1981, 25:461–477.

    PubMed  CAS  Google Scholar 

  5. Whelan HT, Sung JH, Mastri AR: Diffuse leptomeningeal gliomatosis: report of three cases. Clin Neuropathol 1987, 6:164–168.

    PubMed  CAS  Google Scholar 

  6. Civitello LA, Packer RJ, Rorke LB, et al.: Leptomeningeal dissemination of low-grade gliomas in childhood. Neurology 1988, 38:562–566.

    PubMed  CAS  Google Scholar 

  7. Davila G, Duyckaerts C, Lazareth JP, et al.: Diffuse primary leptomeningeal gliomatosis. J Neuro Oncol 1993, 15:45–49.

    Article  CAS  Google Scholar 

  8. Bailey P, Robitaille Y: Primary diffuse leptomeningeal gliomatosis. Can J Neurol Sci 1985, 12:278–281.

    PubMed  CAS  Google Scholar 

  9. Ausman J, Shrontz C, Chason J, et al.: Aggressive choroid plexus papilloma. Surg Neurol 1984, 22:472–476.

    Article  PubMed  CAS  Google Scholar 

  10. Deutsch M: The impact of myelography on the treatment results for medulloblastoma. Int J Rad Oncol Biol Phys 1984, 10:999–1003.

    CAS  Google Scholar 

  11. Jennings MT, Slatkin N, D’Angelo M, et al.: Neoplastic meningitis as the presentation of occult primitive neuroectodermal tumors. J Child Neurol 1993, 8:306–312.

    PubMed  CAS  Google Scholar 

  12. Ross GW, Rubenstein LJ: Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 1989, 70:31–36.

    PubMed  CAS  Google Scholar 

  13. Trigg M, Makuch R, Glaubiger D: Actuarial risk of isolated CNS involvement in Ewing’s sarcoma following prophylactic cranial irradiation and methotrexate. Int J Radiat Oncol Biol Phys 1985, 11:699–702.

    PubMed  CAS  Google Scholar 

  14. Jenkin R, Simpson W, Keen C: Pineal and suprasellar germinomas: Results of treatment. J Neurosurg 1978, 99–107.

  15. Goldwein J, Corn B, Findlay J, et al.: Is craniospinal irradiation required to cure children with malignant (anaplastic) intracranial ependymomas? Cancer 1991, 67:2766–2771.

    Article  PubMed  CAS  Google Scholar 

  16. Olson M, Chernik N, Posner J: Infiltration of the leptomeninges by systemic cancer: a clinical and pathologic study. Arch Neurol 1974, 30:122–137.

    PubMed  CAS  Google Scholar 

  17. Wasserstrom W, Glass J, Posner J: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49:759–772.

    Article  PubMed  CAS  Google Scholar 

  18. Little J, Dale A, Okazaki H: Meningeal carcinomatosis: clinical manifestations. Arch Neurol 1974, 30:138–143.

    PubMed  CAS  Google Scholar 

  19. Theodore WH, Gendelman S: Meningeal carcinomatosis. Arch Neurol 1981, 38:696–699.

    PubMed  CAS  Google Scholar 

  20. Kaplan J, DeSouza T, Farkash A, et al.: Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990, 92:25–29.

    Google Scholar 

  21. Kokkoris C: Leptomeningeal carcinomatosis: how does cancer reach the pia-arachnoid? Cancer 1983, 51:154–160.

    Article  PubMed  CAS  Google Scholar 

  22. Gonzalez-Vitale J, Garcia-Bunuel R: Meningeal carcinomatosis. Cancer 1976, 37:2906–2911.

    Article  PubMed  CAS  Google Scholar 

  23. DeAngelis LM: Current diagnosis and treatment of leptomeningeal metastasis. J Neuro Oncol 1998, 38:245–252.

    Article  CAS  Google Scholar 

  24. Gelber R, Sallan S, Cohen H, et al.: Central nervous system treatment in childhood acute lymphoblastic leukemia. Cancer 1993, 72:261–270.

    Article  PubMed  CAS  Google Scholar 

  25. Ribeiro R, Rivera G, Hudson M, et al.: An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 1995, 13:333–358.

    PubMed  CAS  Google Scholar 

  26. Steinherz P: CNS leukemia: problem of diagnosis, outcome, and treatment. J Clin Oncol 1995, 13:310–313.

    PubMed  CAS  Google Scholar 

  27. Chamberlain M, Kormanik PA: Neoplastic meningitis: a guide to diagnosis and treatment. CNS Drugs 1998, 10:25–41.

    Article  Google Scholar 

  28. Glass J, Melamed M, Chernik N, et al.: Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979, 29:1369–1375.

    PubMed  CAS  Google Scholar 

  29. Chamberlain M, Sandy A, Press G: Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrastenhanced CT of the brain. Neurology 1990, 40:435–438.

    PubMed  CAS  Google Scholar 

  30. Chamberlain MC: Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995, 23:233–238.

    Article  PubMed  CAS  Google Scholar 

  31. Grossman S, Moynihan T: Neurologic complications of systemic cancer: neoplastic meningitis. Neurol Clin 1991, 9:843–856.

    PubMed  CAS  Google Scholar 

  32. Balis F, Savitch J, Bleyer W, et al.: Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985, 3:485–489.

    PubMed  CAS  Google Scholar 

  33. Shapiro W, Young D, Mehta B: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular, and lumbar injections. N Engl J Med 1975, 293:161–166.

    Article  PubMed  CAS  Google Scholar 

  34. Balis F, Holcenberg J, Blaney S: General principles of chemotherapy. In Principles and Practice of Pediatric Oncology. Edited by Pizzo P, Poplack D. Philadelphia: Lippincott, Williams & Wilkins; 2002:237–308.

    Google Scholar 

  35. Frick J, Ritch PS, Hansen RN, Anderson T: Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 1984, 2:365–368.

    PubMed  CAS  Google Scholar 

  36. Donehower RC, Karp JE, Burke PJ: Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986, 70:1059–1065.

    PubMed  CAS  Google Scholar 

  37. Nand S, Messmore H, Patel R, et al.: Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol 1986, 4:571–575.

    PubMed  CAS  Google Scholar 

  38. Heideman R, Cole D, Balis F, et al.: Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989, 49:736–741.

    PubMed  CAS  Google Scholar 

  39. Heideman RL, Packer RJ, Reaman GH, et al.: A phase II evaluation of thiotepa in central nervous system malignancies. Cancer 1992, 72:271–275.

    Article  Google Scholar 

  40. Slevin M, Piall E, Aherne G, et al.: Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983, 1:546–551.

    PubMed  CAS  Google Scholar 

  41. Lopez J, Nassif E, Vannicola P, et al.: Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol 1985, 3:119–124.

    Article  PubMed  CAS  Google Scholar 

  42. Ackland S, Schilsky R: High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987, 5:2017–2031.

    PubMed  CAS  Google Scholar 

  43. Balis F, Poplack D: Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989, 11:74–86.

    PubMed  CAS  Google Scholar 

  44. Chamberlain MC, Kormanik P, Glantz M: Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis. Oncol Rep 1998, 5:521–523.

    PubMed  CAS  Google Scholar 

  45. Pinedo H, Zaharko D, Bull J, et al.: The reversal of methotrexate cytotoxicity to mouse bone marrow cells by Leucovorin and nucleosides. Cancer Res 1976, 36:4418–4424.

    PubMed  CAS  Google Scholar 

  46. Widemann B, Hetherington M, Smithson W, et al.: Carboxypeptidase-G2 as a rescue agent following methotrexate induced renal failure or intrathecal methotrexate overdose [abstract]. Proc Am Assoc Cancer Res 1995:1384.

  47. Walker R, Allen J, Rosen G, Caparros B: Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986, 4:1845–1950.

    PubMed  CAS  Google Scholar 

  48. Bleyer W: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981, 65(Suppl 1):89–98.

    PubMed  Google Scholar 

  49. Strong J, Collins J, Lester C, Poplack D: Pharmacokinetics of intraventricular and intravenous N,N’,N’-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res 1986, 46:6101–6104.

    PubMed  CAS  Google Scholar 

  50. Zimm S, Ettinger L, Holcenberg J, et al.: Phase I and clinical pharmacological study of 6-mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 1985, 45:1869–1873.

    PubMed  CAS  Google Scholar 

  51. Adamson P, Zimm S, Ragab A, et al.: A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol 1990, 26:343–344.

    Article  PubMed  CAS  Google Scholar 

  52. Blaney S, Cole D, Balis F, et al.: Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993, 53:725–727.

    PubMed  CAS  Google Scholar 

  53. Blaney SM, Phillips PC, Packer RJ, et al.: Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996, 78:527–531.

    Article  PubMed  CAS  Google Scholar 

  54. Friedman HS, Kerby T, Fields S, et al.: Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer 1999, 85:1160–1165.

    Article  PubMed  CAS  Google Scholar 

  55. Macdonald D, Cairncross G, Stewart D, et al.: Phase II study of Topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 1996, 7:205–207.

    PubMed  CAS  Google Scholar 

  56. Oberhoff C, Kieback DG, Wurstlein R, et al.: Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 2001, 24:256–260.

    Article  PubMed  CAS  Google Scholar 

  57. Blaney SM, Takimoto C, Murry DJ, et al.: Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol 1998, 41:464–468.

    Article  PubMed  CAS  Google Scholar 

  58. Friedman HS, Petros WP, Friedman AH, et al.: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999, 17:1516–1525.

    PubMed  CAS  Google Scholar 

  59. Chamberlain MC: Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neuroncol 2002, 56:183–188.

    Article  Google Scholar 

  60. Chamberlain MC: Salvage chemotherapy with CPT-11 for oligodendroglioma. J Neurooncol 2002, 59:157–163.

    Article  PubMed  Google Scholar 

  61. Balis F, Lester C, Chrousos G, et al.: Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 1987, 5:202–207.

    PubMed  CAS  Google Scholar 

  62. Jones B, Freeman AI, Shuster JJ, et al.: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991, 19:269–275.

    Article  PubMed  CAS  Google Scholar 

  63. Hurwitz CA, Silverman LB, Schorin MA, et al.: Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000, 88:1964–1969.

    Article  PubMed  CAS  Google Scholar 

  64. Glantz MJ, Jaeckle KA, Chamberlain MC, et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5:3394–3402. One of two recent randomized clinical trials comparing sustainedrelease Ara-C with methotrexate in adults with neloplastic meningitis secondary to solid cancer.

    PubMed  CAS  Google Scholar 

  65. Glantz M, Chamberlain MC, Shapiro W, et al.: A randomized trial of a slow-release formulation of cytarabine for the treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110–3116. One of two recent randomized clinical trials comparing sustained release Ara-C with standard Ara-C and the only randomized trial in patients with lymphomatous meningitis.

    PubMed  CAS  Google Scholar 

  66. Tallal L, Tan C, Oettgen H, et al.: E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 1970, 25:306–320.

    Article  PubMed  CAS  Google Scholar 

  67. Capizzi R, Bertino J, Skeel R, et al.: L-Asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971, 74:893–901.

    PubMed  CAS  Google Scholar 

  68. Ho D, Brown N, Yen A, et al.: Clinical pharmacology of polyethylene glycol L-asparaginase. Drug Metab Dispos 1986, 14:349–352.

    PubMed  CAS  Google Scholar 

  69. Berg S, Balis F, McCully C, et al.: Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the Rhesus monkey. Cancer Chemother Pharmacol 1993, 32:310–314.

    Article  PubMed  CAS  Google Scholar 

  70. Riccardi R, Holcenberg J, Glaubiger D, et al.: L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981, 41:4554–4558.

    PubMed  CAS  Google Scholar 

  71. Collins J: Pharmacokinetics of intraventricular administration. J Neurooncol 1983, 1:283–291.

    Article  PubMed  CAS  Google Scholar 

  72. Blasberg R, Patlak C, Shapiro W: Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep 1977, 61:633–641.

    PubMed  CAS  Google Scholar 

  73. Chamberlain MC, Corey-Bloom J: Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology 1991, 41:1765–1769.

    PubMed  CAS  Google Scholar 

  74. Larson S, Schall G, DiChiro G: The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nuclear Med 1971, 12:555–557.

    CAS  Google Scholar 

  75. Hitchens R, Bell D, Woods R, et al.: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987, 5:1655–1662.

    Google Scholar 

  76. Giannone L, Greco F, Hainsworth J: Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986, 4:68–73.

    PubMed  CAS  Google Scholar 

  77. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al.: Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993, 11:561–569.

    PubMed  CAS  Google Scholar 

  78. Blaney S, Balis F, Murphy R, et al.: A phase I study of intrathecal mafosfamide in patients with refractory meningeal malignancy [abstract]. Proc ASCO 1992, 11:274.

    Google Scholar 

  79. Slavc I, Schuller E, Czech T, et al.: Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 1998, 38:213–218.

    Article  PubMed  CAS  Google Scholar 

  80. Blaney S, Horowitz M, Kun L, et al.: A new approach to the treatment of infants with CNS tumors. Presentation at the Society for Neuro-Oncology. San Francisco, CA, June 11, 2000.

  81. Bigner DD, Brown M, Coleman RE, et al.: Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab’) 2: a preliminary report. J Neurooncol 1995, 24:109–122.

    Article  PubMed  CAS  Google Scholar 

  82. Brown MT, Coleman RE, Friedman AH, et al.: Intrathecal 131Ilabeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996, 2:963–972.

    PubMed  CAS  Google Scholar 

  83. Hall WA, Fodstad O: Immunotoxins and central nervous system neoplasia. J Neurosurg 1992, 76:1–12.

    PubMed  CAS  Google Scholar 

  84. Kemshead JT, Hopkins KI, Chandler CL: Treatment of diffuse leptomeningeal malignancy by intrathecal injection of 131I radioimmunoconjugates. Recent Results Cancer Res 1996, 141:145–158.

    PubMed  CAS  Google Scholar 

  85. Kemshead JT, Hopkins K, Pizer B, et al.: Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies. Br J Cancer 1998, 77:2324–2330.

    PubMed  CAS  Google Scholar 

  86. Moseley RP, Papanastassiou V, Zalutsky MR, et al.: Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer 1992, 52:38–43.

    Article  PubMed  CAS  Google Scholar 

  87. Youle RJ: Immunotoxins for central nervous system malignancy. Semin Cancer Biol 1996, 65–70.

  88. Chamberlain MC: A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 2002, 94:2675–2680.

    Article  PubMed  CAS  Google Scholar 

  89. Berg S, Balis F, Zimm S, et al.: Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992, 10:143–148.

    PubMed  CAS  Google Scholar 

  90. Arndt C, Colvin O, Balis F, et al.: Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys. Cancer Res 1987, 47:5932–5934.

    PubMed  CAS  Google Scholar 

  91. Bleyer W, Poplack D, Simon R: ’Concentration x time’ methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978, 51:835–842.

    PubMed  CAS  Google Scholar 

  92. Chamberlain M, Dirr L: Involved field radiotherapy and intraommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitis. J Clin Oncol 1993, 11:1978–1984.

    PubMed  CAS  Google Scholar 

  93. Chamberlain MC, Kormanik P: Leptomeningeal metastases due to melanoma: combined modality therapy. Int J Oncol 1996, 9:505–510.

    Google Scholar 

  94. Chamberlain MC, Kormanik PA: Carcinomatous meningitis secondary to breast cancer: combined modality therapy. J Neurooncol 1997, 35:55–64.

    Article  PubMed  CAS  Google Scholar 

  95. Chamberlain MC, Kormanik PA: Carcinomatous meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998, 55:506–512.

    Article  PubMed  CAS  Google Scholar 

  96. Chamberlain MC, Kormanik PA: Non-AIDS related lymphomatous meningitis: combined modality therapy. Neurology 1997, 49:1728–1731.

    PubMed  CAS  Google Scholar 

  97. Chamberlain MC, Kormanik PA: Lymphomatous meningitis in immunocompromised patients: combined modality therapy. Oncol Rep 1998, 5:521–525.

    PubMed  CAS  Google Scholar 

  98. Jaeckle KA, Phuphanich S, Bent MJ, et al.: Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001, 84:157–163. An excellent review of the treatment of women with breast cancer and neoplastic meningitis.

    Article  PubMed  CAS  Google Scholar 

  99. Chamberlain MC, Kormanik PA: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997, 87:694–699.

    Article  PubMed  CAS  Google Scholar 

  100. Lishner M, Perrin R, Feld R, et al.: Complications associated with ommaya reservoirs in patients with cancer. Arch Intern Med 1990, 150:173–176.

    Article  PubMed  CAS  Google Scholar 

  101. Ochs J: Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 1989, 11:93–105.

    PubMed  CAS  Google Scholar 

  102. Bleyer W, Drake J, Chabner B: Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973, 289:770–773.

    Article  PubMed  CAS  Google Scholar 

  103. Price R: Therapy related central nervous system diseases in children with acute lymphocytic leukemia. In Central Nervous System Leukemia. Edited by Mastrangelo R, Poplack D, Riccardi R. Boston: Martinus Nijhoff Publishers; 1983:71–81.

    Google Scholar 

  104. Addegio J, Ridgway D, Bleyer W: The acute management of intrathecal methotrexate overdose: pharmacologic rationale and guidelines. J Pediatr 1981, 98:825–828.

    Google Scholar 

  105. Pochedly C: Prevention of meningeal leukemia: review of 20 years of research and current recommendations. Hematol Oncol Clin North Am 1990, 4:951–969.

    PubMed  CAS  Google Scholar 

  106. Adamson PC, Balis FM, McCully CL, et al.: Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. J Clin Oncol 1991, 9:670–674.

    PubMed  CAS  Google Scholar 

  107. Bleyer W, Poplack D: Intraventricular versus intralumbar methotrexate for central nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979, 6:207–213.

    Article  PubMed  CAS  Google Scholar 

  108. Bleyer W, Coccia P, Sather H, et al.: Reduction in the incidence of central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1983, 1:317–325.

    PubMed  CAS  Google Scholar 

  109. Saiki J, Thompson S, Smith F, Atkinson R: Paraplegia following intrathecal chemotherapy. Cancer 1972, 29:370–374.

    Article  PubMed  CAS  Google Scholar 

  110. Bleyer WA: Intrathecal depot cytarabine therapy: a welcome addition to the therapeutic armamentarium. Clin Cancer Res 1999, 5:3349–3351.

    PubMed  CAS  Google Scholar 

  111. Boogerd W, Hart AAM, Van der Sande JJ, et al.: Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer 1991, 67:1685–1695.

    Article  PubMed  CAS  Google Scholar 

  112. Fizazi K, Asselain B, Vincent-Salomon A, et al.: Meningeal carcinomatosis in patients with breast carcinoma. Cancer 1996, 77:1315–1323.

    Article  PubMed  CAS  Google Scholar 

  113. Glantz M, Hall WA, Cole BF, et al.: Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow studies. Cancer 1995, 75:2919–2931.

    Article  PubMed  CAS  Google Scholar 

  114. Balm M, Hammack J: Leptomeningeal carcinomatosis. Arch Neurol 1996, 53:626–632.

    PubMed  CAS  Google Scholar 

  115. Siegal T, Lossos A, Pfeffer MR: Leptomeningeal metastasis: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994, 44:1463–1469.

    PubMed  CAS  Google Scholar 

  116. Chamberlain MC, Kormanik P: Prognostic significance of 111Indium-DTPA CSF flow studies. Neurology 1996, 46:1674–1677.

    PubMed  CAS  Google Scholar 

  117. Chamberlain MC, Kormanik PA: Prognostic significance of co-existent bulky metastatic CNS disease in patients with leptomeningeal metastases. Arch Neurol 1997, 54:1364–1368.

    PubMed  CAS  Google Scholar 

  118. Grossman S, Trump D, Chen D, et al.: Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. Am J Med 1982, 73:641–647.

    Article  PubMed  CAS  Google Scholar 

  119. Glantz M, Chamberlain MC, Walters BC: Diagnosis and outcome measures for neoplastic meningitis: a review of the literature and clinical experience. Neurosurg Focus 1998, 4:8–16.

    Article  Google Scholar 

  120. Dedrick R, Zaharko D, Bender R, et al.: Pharmacokinetic considerations on resistance to anticancer drugs. Cancer Chemother Rep 1975, 59:795–804.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Southern California, Norris Comprehensive Cancer Center and Hospital, 1441 Eastlake Avenue, 90033-0804, Los Angeles, CA, USA

    Marc C. Chamberlain MD

Authors
  1. Stacey L. Berg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc C. Chamberlain MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berg, S.L., Chamberlain, M.C. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 5, 29–40 (2003). https://doi.org/10.1007/s11912-003-0084-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-003-0084-9

Keywords

Search

Navigation